2 results
Approved WMOCompleted
Primary: efficacy and safety of the addition of UMEC 62.5mcg once daily to ICS/LABA therapy, compared with placebo over 12 weeks in subjects with COPD.Secondary: effect of the addition of UMEC to ICS/LABA therapy on COPD-related health status…
Approved WMOCompleted
Primary Objective:Evaluating the predictive value of CAUS to assess the steatosis severity, combining multiple CAUS parameters (RAC, LAT, SNR, MU, AX), with 1H-MRS as a reference in adult patients with CIF.Secondary Objective(s):-To assess the…